Far East Bio-Tec Co., Ltd.

Chuang-Chun Chiuh

Yi-Hsiang Chen

Shin-Ru Shih

Gi-Kung Chang

Jing-Yun Chen

Ya-Chun Liao

Xin-Wen Huang

Wei Chen

Tz-Chong Chou

Shau-Feng Chang

I-Chen Hu

Chun-Wei Cheh

Ming-Shun Wu

Disclosed herein is the use a cyanobacterial biomass for treating hepatitis B virus (HBV) infection, in particular, chronic HBV infection. According to various embodiments of the present disclosure, the cyanobacterial biomass, upon administration of at least one month, significantly reduces the level of the surface antigen of hepatitis B virus (HBsAg) detectable in the subject receiving the treatment and/or mitigates insomnia associated with chronic HBV infection.

Use of cyanobacterial biomass in treating hepatitis B virus infection

The present disclosure provides various cyanobacterial extracts exhibiting antiviral activity to a wide spectrum of viruses, such as enterovirus (EV), respiratory syncytial virus (RSV), Human Herpesvirus (HHV), Ebola virus, porcine epidemic diarrhea virus (PEDV), and porcine reproductive and respiratory syndrome virus (PRRSV). The cyanobacterial extract is prepared from biomass of(or). Also disclosed herein are process for preparing the cyanobacterial extract and uses of the cyanobacterial extract.

Antiviral arthrospira maxima extract

A composition of algal extracts containing phycobiliprotein is provided. This composition not only effectively inhibit the growth of oral pathogens includingand, but also reduces the inflammation caused by those pathogens. Therefore, the phenomenon of alveolar bone loss in periodontal patients is mitigation, achieving the effect of prevention and treatment of periodontal disease.

Composition of algal extracts for preventing and treating periodontal disease

Disclosed is a pharmaceutical composition for inhibiting infection and replication of influenza A and B virus, and the manufacture thereof. The pharmaceutical composition is produced by a manufacture of low-temperature disintegrating cyanobacteria, comprising the steps of: (a) mixing cyanobacteria and non-organic solvent to form a suspension containing cyanobacteria; (b) freezing the suspension with a temperature below 0&#xb0; C. to form a ice block and the ice block being melted at a low temperature, the whole step being repeated at least twice; (c) separating the cyanobacterial residues and extract solution of the suspension; and (d) collecting the isolated cyanobacterial extract solution; wherein the cyanobacterial extract solution is a solution containing cyanobacterial bioactive substances. The pharmaceutical composition is able to effectively inhibit binding of sialic acid and hemagglutinin of influenza A and/or B virus, so as to inhibit infection and replication of influenza virus. Further, this pharmaceutical composition is able to inhibit infection of influenza virus resistant to neuraminidase inhibitors.

Pharmaceutical composition for inhibiting infection and replication of influenza A and B virus, and the manufacture thereof

Growing community of inventors

Taipei, Taiwan

Chuang-Chun Chiuh